ArticleOpen forum infectious diseases2025
Epitope-Specific Antibody Immunodominance Driving Antibody and Influenza Viral Evolution During 2010- 2024.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding hemagglutination inhibition antibody immunodominance (HAI-Ab-ID) is key to forecasting influenza virus antigenic drift and improving vaccine strain selection. We explored epitope-specific HAI-Ab-IDs in adults immunized with A/California/07/2009-like (CA/09) vaccine and A(H1N1)pdm09 viral evolutions. Methods: Sera from adults (N = 300; birth year, 1961-1998) collected from 2010 to 2016 were analyzed in HAI assays. To determine epitope-specific HAI-Ab-IDs, 4 reverse genetics (RG) viruses were generated: RG-wt possessing CA/09 wild type hemagglutinin and 3 RG mutants containing K163Q, K130 deletion, or D127N/N129T mutations. To analyze cross-reactive or strain-specific HAI-Ab-IDs, 10 historical 1977-2007 A(H1N1) viruses were used. Antibody adsorption assays were used to verify the specificity of HAI-Ab-IDs. Publicly available sequences of A(H1N1)pdm09 viruses from GISAID (Global Initiative on Sharing All Influenza Data; n = 100 277, 2010-2024) were analyzed for viral evolution. Results: Four HAI-Ab-IDs targeting the epitopes possessing K163, D127 + N129 + K130, K130, or D127 + N129 were detected in >50% donors during 2010 to 2016. Three HAI-Ab-IDs (K163-Ab-IDs, D127/N129/K130-Ab-IDs, and K130-Ab-IDs) cross-inhibited some 1977-2007 viruses. Conversely, D127/N129-Ab-ID showed no cross-inhibition with historical 1977-2007 viruses. Low proportions of K130-Ab-IDs were presented mainly in prevaccination sera. Shifts of cross-reactive HAI-Ab-IDs to strain-specific D127/N129-Ab-ID occurred between 2010 and 2016. The HAI-Ab-IDs exerted immune selection pressures on hemagglutinin (4 positions: D127, N129, K130, and K163). So far, 3 escape mutations became fixed in the 2013-2014 season (K163Q), 2020-2021 season (N129D), and 2022-2023 season (K130N). Conclusions: HAI-Ab-IDs were common phenomena in adults from 2010 to 2016. Preexisting HAI-Ab-IDs drove viral and antibody evolutions by HAI-Ab-mediated immune selection and suppression. Monitoring viral and HAI-Ab-ID evolution is of great importance to improve vaccine effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.